Compare Intuitive Surgical, Inc. (ISRG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs TG Therapeutics Inc — how do they compare? Intuitive Surgical, Inc. trades at $351.36 (market cap $125.08B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Intuitive Surgical, Inc. is far larger — about 15.1× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ISRG | TGTX | |
|---|---|---|
Market Cap | $125.08B | $8.26B |
Sector | Health | Health |
52-Week High | $592.85 | $59.06 |
52-Week Low | $345.42 | $26.39 |
Enterprise Value | $116.45B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $350.06, down 1.34% on the day and near its 52-week low of $344.55. The stock is in a bearish technical trend despite strong fundamentals: Q2 2026 EPS beat estimates at $2.80 vs. $2.48 expected, revenue grew to $10.06B in 2025, and net income margin expanded to 28.45%. However, slowing U.S. procedure growth and a cautious 2026 outlook have pressured shares, with recent news highlighting a nearly 40% decline year-to-date.
The outlook remains mixed: robust profitability and a 69.6% analyst buy rating with a $504.56 consensus target suggest long-term value, but near-term risks include valuation concerns (P/E 40.5), competitive pressures, and macroeconomic headwinds. Investors face a divergence between solid execution and market sentiment driven by growth deceleration fears.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
